热门资讯> 正文

Ionis因Angelman综合症药物获得FDA突破性治疗地位

2025-09-09 23:18

Ionis Pharmaceuticals (NASDAQ:IONS) said on Tuesday that the U.S. FDA has granted breakthrough therapy status to its antisense medicine, ION582, for the treatment of angelman syndrome, a neurological disease.
This designation is based on results from a trial of ION582 that showed consistent improvement on domains including communication, cognition and motor function, as well as favorable safety and tolerability.
The breakthrough therapy designation from the FDA is intended to expedite the review of medicines that treat a serious or life-threatening condition.
The stock is up about 3% today.

More on Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)
Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Positive CORE and CORE2 Topline Results
Ionis upgraded at BMO Capital Markets after data for lipid-lowering agent
Ionis gains on late-stage trial win for hypertriglyceridemia therapy

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。